Pharmacovigilance analysis of polatuzumab plus bendamustine and rituximab treatment protocol: identifying comprehensive safety signals using FDA database

Pharmacovigilance analysis of polatuzumab plus bendamustine and rituximab treatment protocol: identifying comprehensive safety signals using FDA database

BackgroundThe combination of polatuzumab, bendamustine and rituximab (pola+BR) was authorized for the treatment of relapsed or refractory Diffuse large B cell lymphoma (DLBCL). This study used the FDA database to identify safety signals related to the treatment protocol.MethodsThe adverse events (AE...

Full description

Saved in:
Bibliographic Details
Main Authors: Fang Wu, Siliang Wang, Xihui Xu, Weihui Zhang, Jie Zhou, Runyan Niu, Wenting Cai, Yonggong Yang, Mengying Liu, Jinping Zhang
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-02-01
Series:Frontiers in Pharmacology
Subjects:
pharmacovigilance
polatuzumab vediton
drug safety
disproportionality analysis
FAERS
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2025.1459067/full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2025.1459067/full

Similar Items